Aptalis Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bridgewater NJ United States (2011)
Status: Acquired by Forest Laboratories (2014) → now AbbVie (2019)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1951

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

APTALIS PHARMA US

Active Ingredients

Marketed Drugs (1)

dicyclomine hydrochloride (bentyl) (1951)

Drugs in Phase 4 Trials (1)

Key: Aptalis (0) Acquired (1)

pancrelipase (creon) (3 trials)

Drugs in Phase 3 Trials (12)

Key: Aptalis (0) Acquired (12)

Bismuth Subcitrate Potassium (Pylera) (2 trials)

clarithromycin (biaxin) (1 trial)

itropride (1 trial)

Lactobacillus acidophilus (1 trial)

lamivudine (epivir) (1 trial)

mesalamine (rowasa) (1 trial)

metronidazole (flagyl) (1 trial)

omeprazole (prilosec) (2 trials)

procaine benzylpenicillin (novocaine) (1 trial)

tetracycline (tetrex) (1 trial)

ursodeoxycholic acid (2 trials)

zidovudine (retrovir) (1 trial)

Drugs in Phase 2 Trials (1)

Key: Aptalis (0) Acquired (1)

porfimer (photofrin) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Aptalis (0) Acquired (1)

eur-1066 (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 12
  • # of Trial APIs: 15